CBR1 Recombinant Antibody, FITC Conjugated
Product Specifications
Background
NADPH-dependent reductase with broad substrate specificity. Catalyzes the reduction of a wide variety of carbonyl compounds including quinones, prostaglandins, menadione, plus various xenobiotics. Catalyzes the reduction of the antitumor anthracyclines doxorubicin and daunorubicin to the cardiotoxic compounds doxorubicinol and daunorubicinol.
Synonyms
15 hydroxyprostaglandin dehydrogenase [NADP+]; Carbonyl reductase [NADPH] 1; CBR1; CRN; NADPH dependent carbonyl reductase 1; Prostaglandin 9 ketoreductase; SDR21C1.
Gene ID
873
Swiss Prot
P16152
Cellular Locus
Cytoplasm
Host
Rabbit
Cross Reactivity
Human
Target
CBR1
Clonality
Recombinant
Isotype
IgG
Conjugation
FITC
Source
KLH conjugated synthetic peptide derived from human CBR1
Applications
WB, IF
Purification
Purified by Protein A.
Excitation Emission
494nm/518nm
Concentration
Lot dependent
Dilution
WB (1:300-5000), IF ()
Buffer
Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Modification
Unmodified
Storage Conditions
Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
Gene ID URL
873
Available Sizes
More Discoveries
Explore Other Products
Browse additional items from our catalog
039738-ML650 100 µL
PCDHA9, NT (PCDHA9, KIAA0345, Protocadherin alpha-9) (MaxLight 650) discontinued
Sign In for Pricing
View Details 
326958 100 µL
ORC5L (Origin Recognition Complex Subunit 5, ORC5, ORC5P, ORC5T, PPP1R117)
Sign In for Pricing
View Details 